DN-HCC及DN患者超声造影及CEUS LI-RADS标准分类结果观察

摘要/Abstract

摘要： 目的探讨异型增生结节伴局灶性肝细胞癌(DN-HCC)及异型增生结节(DN)患者超声造影(CEUS)表现及CEUS肝脏影像报告和数据系统(CEUS LI-RADS)标准分类结果。方法 2019年10月至2021年10月北京市大兴区人民医院收治的肝脏局灶性病变患者78例(80个病灶,其中DN 12个,DN-HCC 68个),接受CEUS检查。根据CEUS LI-RADS v2017标准,对所有病灶进行分类。结果 DN组动脉期同步等增强占比为66.7%,显著高于DN-HCC组的13.2%(P<0.05);DN组动脉期高增强占比为16.7%,显著低于DN-HCC组的58.8%(P<0.05)。DN组病灶动脉期和延迟期CEUS增强模式有三种,低/等占25.0%,等/等占66.7%,高/高占8.3%;DN-HCC组CEUS增强模式包括六种,其中等/等占4.4%,低/低占5.9%,等/低占8.8%,低/等占13.2%,高(含局部高增强)/低占29.4%,高(含局部高增强)/等占38.2%。DN组CEUS LI-RADS v2017标准分类中LR-3类占比为100.0%,高于DN-HCC组的26.5%(P<0.05)。结论 CEUS动脉期高增强或延迟期减退对DN与DN-HCC具有鉴别意义,值得临床验证。

关键词: 异型增生结节, 局灶性肝细胞癌, 超声造影, 肝脏影像报告与数据系统

Abstract: Objective To investigate the contrast-enhanced ultrasound (CEUS) findings and the standard classification results of CEUS liver image reporting and data system (CEUS LI-RADS) in patients with dysplastic nodules with focal hepatocellular carcinoma (DN-HCC) and dysplastic nodules (DN). Methods 78 patients with hepatic focal lesions (80 lesions, including 12 DN and 68 DN-HCC) admitted to our hospital between October 2019 and October 2021, and all patients underwent CEUS examination. All lesions were classified according to CEUS Li-RADS V2017 criteria. Results The proportion of synchronous enhancement in arterial phase in DN group was 66.7%, which was significantly higher than 13.2% in DN-HCC group (P<0.05); The proportion of high enhancement in arterial phase in DN group was 16.7%, which was significantly lower than 58.8% in DN-HCC group (P<0.05). In the DN group, there were three CEUS enhancement modes in arterial phase and delayed phase, of which low / equal accounted for 25.0%, equal/equal accounted for 66.7%, and high / high accounted for 8.3%;There were six CEUS enhancement modes in dn-hcc group, of which equal/equal accounted for 4.4%, low / low accounted for 5.9%, equal/low accounted for 8.8%, low/equal accounted for 13.2%, high (including local high enhancement) / low accounted for 29.4%, and high (including local high enhancement)/equal accounted for 38.2%. The proportion of LR-3 in CEUS LI-RADS v2017 standard classification in DN group was 100.0%, which was higher than 26.5% in DN-HCC group (P<0.05).Conclusion CEUS arterial phase high enhancement or delayed phase decline has differential significance between DN and DN-HCC, which is worthy of clinical verification.

Key words: Dysplastic nodule, Focal hepatocellular carcinoma, Contrast enhanced ultrasound, Liver imaging reporting and data system

师旭, 乔向彬, 刘佳, 肖保军. DN-HCC及DN患者超声造影及CEUS LI-RADS标准分类结果观察[J]. 肝脏, 2023, 28(1): 79-82.

SHI Xu, QIAO Xiang-bin, LIU Jia, XIAO Bao-jun. Contrast ultrasonography and CEUS LI-RADS standard classification of DN-HCC and DN patients were observed[J]. Chinese Hepatolgy, 2023, 28(1): 79-82.

参考文献

[1] Liu Z, Jiang Y, Yuan H, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the global burden of disease study 2016 and implications for liver cancer prevention. J Hepatol, 2019, 70(4):674-683.
[2] Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology, 2019, 156(2):477-491.
[3] 李小娟, 黄品同, 徐永远, 等. 超声造影肝影像报告和数据系统与磁共振肝影像报告和数据系统对肝细胞癌高危患者肝占位性病变的一致性评价研究. 中华超声影像学杂志, 2020, 29(6):522-528.
[4] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604.
[5] 高芬, 蔡萍, 刘晨, 等. 肝细胞癌癌前结节影像学特征的研究进展. 中华肝脏病杂志, 2020, 28(1):9-13.
[6] Marrero JA, Ahn J, Rajender Reddy K. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol, 2014, 109(9):1328-1347.
[7] Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med, 2013, 34(1):11-29.
[8] Kono Y, Lyshchik A, Cosgrove D, et al. Contrast enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS): the official version by the American College of Radiology (ACR). Ultraschall Med, 2017, 38(1):85-86.
[9] 丁建民, 龙磊, 周洪雨, 等. 超声造影肝脏影像报告与数据系统对高危人群肝细胞癌的风险预测. 中华超声影像学杂志, 2020, 29(2):138-142.
[10] 中国抗癌协会肝癌专业委员会, 中华医学会肝病学分会肝癌学组, 中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝胆外科杂志, 2015, 21(3):145-151.
[11] Joo I, Kim SY, Kang TW, et al. Radiologic-pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced MRI: a multicenter study. Radiology. 2020, 296(2):335-345.
[12] Liu D, Liu F, Xie X, et al. Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound. Eur Radiol, 2020, 30(4):2365-2376.
[13] Ainora ME, Iezzi R, Ponziani FR, et al. Contrast-enhanced ultrasound in the short-term evaluation of hepatocellular carcinoma after locoregional treatment. Dig Dis, 2020, 38(6):522-533.
[14] 陈彦玲, 王文平. 超声造影在肝细胞性肝癌诊疗中的应用进展. 中华超声影像学杂志, 2020, 29(10):916-920.
[15] Duan Y, Xie X, Li Q, et al. Differentiation of regenerative nodule, dysplastic nodule, and small hepatocellular carcinoma in cirrhotic patients: a contrast-enhanced ultrasound-based multivariable model analysis. Eur Radiol, 2020, 30(9):4741-4751.
[16] Renzulli M, Biselli M, Brocchi S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut, 2018, 67(9):1674-1682.
[17] Fan PL, Xia HS, Ding H, et al. Characterization of early hepatocellular carcinoma and high-grade dysplastic nodules on contrast-enhanced ultrasound: correlation with histopathologic findings. J Ultrasound Med, 2020, 39(9):1799-1808.
[18] Wu W, Chen M, Yan K, et al. Evaluation of contrast-enhanced ultrasound for diagnosis of dysplastic nodules with a focus of hepatocellular carcinoma in liver cirrhosis patients. Chin J Cancer Res, 2015, 27(1):83-89.
[19] Park HJ, Choi BI, Lee ES, et al. How to differentiate borderline hepatic nodules in hepatocarcinogenesis: emphasis on imaging diagnosis. Liver Cancer, 2017, 6(3):189-203.